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Abstract: Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all 
patients derive clinical beneﬁ  t from such a treatment. Hence, the development of predictive biomarkers able to identify lung 
cancer patients who are most likely to beneﬁ  t from cisplatin-based chemotherapy has become a scientiﬁ  c priority. Among 
the molecular pathways involved in DNA damage control after chemotherapy, the nucleotide excision repair (NER) is a 
critical process for the repair of DNA damage caused by cisplatin-induced DNA adducts. Many reports have explored the 
role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cispla-
tin-induced DNA adducts in cancer cells.
Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, 
the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in 
chemo-naïve patients. On the contrary, the beneﬁ  t of adjuvant cisplatin-based chemotherapy was more profound in patients 
with low ERCC1 expression. In a prospective cohort studying mRNA expression in tumor biopsies from patients receiving 
customized therapy with cisplatin and gemcitabine depending on the molecular proﬁ  le of the tumour, results showed that 
patients with low ERCC1 mRNA expression had a longer median survival compared to those with high expression. These 
data suggest the potent use of ERCC1 as a molecular predictor of clinical resistance to platinum-based chemotherapy in the 
adjuvant setting of NSCLC. Nevertheless, optimization of methodology, including standardization of technical procedures, 
as well as validation of ERCC1 protein expression in large prospective cohorts, seem necessary before any routine immu-
nohistochemical validation of ERCC1 can be implemented in daily practice.
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Introduction
Accounting for approximately 1,000,000 deaths every year and characterized by an increasing annual 
incidence of 0.5%, lung cancer remains the leading cause of cancer-related death worldwide [Spiro and 
Porter, 2002]. Response rates to chemotherapy for inoperable NSCLC vary from 30 to 60% for platinum 
combined with either gemcitabine or vinorelbine or a taxane. Although platinum-based chemotherapy 
regimens have demonstrated clinical activity against NSCLC, advanced disease remains fatal with short 
survival outcomes (approximately 5% at 5 years) [Dunant et al. 2005]. As a consequence, one of the 
most important challenges currently in medical oncology is to identify an optimal treatment strategy 
using individualized approaches. In the future, these will certainly be based on a precise knowledge of 
the tumor’s molecular signature [Blackhall and Thatcher, 2004].
Pre-clinical studies have already produced large amounts of information able to elucidate the bio-
logical mechanisms of cancer cell response to the stress of chemotherapy. From in vitro studies using 
lung cancer cell lines, more than 100 candidate genes have been identiﬁ  ed as potent biomarkers of 
chemosensitivity [Sekine et al. 2006]. Those are genes implicated in physiological processes such as 
drug transport, drug metabolism, DNA repair, cell cycle regulation, and apoptotic or anti-apoptotic 
pathways. Among them, mechanisms of DNA repair play a crucial role in the preservation of genome 
integrity. They also allow to circumvent the damages induced by a large number of chemotherapeutic 
agents and thus contribute to clinical resistance to anticancer drugs. However, only few of the biomark-
ers related to DNA damage repair process are of clinical interest in lung cancer. Currently, the most 220
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extensively studied markers are ribonucleotide 
reductase M1 subunit (RRM1), which is implicated 
in the metabolism of nucleotides for DNA synthe-
sis, p53 (implicated in the apoptotic response), and 
the excision repair cross-complementation group 
1 (ERCC1), implicated in DNA repair. In the cur-
rent review we describe the origin of the main DNA 
lesions, we refer to mechanisms of DNA repair and 
we focus on the role of ERCC1 as a molecular 
determinant of resistance to cisplatinum-based 
chemotherapy in NSCLC.
DNA Lesions and Mechanisms 
of DNA Repair
DNA lesions are generally classiﬁ  ed into three cat-
egories (Fig. 1): (1) Breaks of endogenous origin 
that include products of the cellular metabolism 
leading often to the spontaneous rupture of the gly-
cosidic bond between the nucleosidic base and the 
deoxyribose, resulting in a simple break of DNA 
sequence which may, in rare cases, provoke 
irreversible damage and consequent cellular death 
[Friedberg, 2003]. A critical mechanism of 
endogenous DNA damage is the formation of free 
radicals produced in the mitochondrial respiration 
chain. Such molecules can directly react with the 
DNA molecule and form more than 100 different 
oxidative lesions [Beckman and Ames, 1997]. (2) 
Breaks of exogenous origin related to several 
environmental factors including the ultraviolet 
component of sunlight, which can induce the forma-
tion of dimers (DNA adducts). Some genotoxic 
substances contained in cigarette smoke (benzopy-
renes) or in industrial waste are equally capable of 
provoking the formation of DNA adducts [Scharer, 
2003]. (3) Finally, some anti-neoplastic drugs can
generate DNA breaks depending on the mechanism 
of the action and the pharmacological proper-
ties of the molecule. These agents include the nitro-
sureas (carmustine, lomustine, fotemustine, 
streptozokine), the tetrazines (temozolamide, 
Figure 1. The main endogenous and exogenous mechanisms that can induce DNA damage (upper line), along with the main cellular 
mechanisms of DNA damage repair (lower line) Reproduced with permission.221
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dacarbazine), the aziridines (thiotepa, mitomycin C), 
the bischloroethylamines (melphalan, chlorambucil) 
and notably the platinum combounds (cisplatin, 
carboplatin, oxaliplatin). The most frequent type of 
DNA damage inﬂ  icted by these agents is the forma-
tion of O
6-methylguanine which can generate an 
irreversible error in DNA replication process, 
inevitably leading in cellular death [Bignami et al. 
2000]. Finally, stabilisation of DNA topo-isomerases 
I and II by their corresponding inhibitors (campto-
thecins and epipodophyllotoxins) can result in 
simple or double chain break of the DNA molecule, 
inducing irreversible DNA damage [Wang, 1996].
In recent years, studies on mechanisms of che-
motherapy resistance have focused on the identi-
ﬁ  cation of molecular markers involved in critical 
pathways through which the anti-neoplastic action 
of the drug is exerted. In the case of platinum 
compounds, the establishment of DNA lesions by 
covalent binding of platinum to the DNA molecule 
(commonly mentioned as DNA “adducts”) consti-
tutes cisplatin’s main cytotoxic mechanism. Unfor-
tunately, some cancer cells are able to circumvent 
drug action through increased DNA-repair capac-
ity. ERCC1 enzyme is a rate-limiting DNA repair 
protein in the NER pathway that is speciﬁ  cally in 
charge of removing DNA platinum adducts 
[Lindahl and Wood, 1999; Mu et al. 1996; Sancar, 
1994; Zamble et al. 1996].
The NER pathway contains several steps, 
including the recognition of the lesion, opening of 
the double DNA helix around the damage, excision 
of the DNA strand carrying the platinum adduct, 
and ultimately polymerization of a new DNA 
strand followed by its ligation [Mu et al. 1996]. 
The NER process comprises at least 16 different 
proteins, including the XP proteins (groups A to G), 
the deﬁ  ciency of which provokes a rare syndrome 
called xeroderma pigmentosum (XP), characterized 
by hypersensitivity to ultraviolet radiation and a 
predesposition to skin cancer [Evans et al. 1997]. 
The NER pathway consists of two distinct molec-
ular processes: The GG-NER (Global Genome 
NER), which repairs DNA lesions independently 
of their localisation in the genome, and the 
TC-NER (Transcription-Coupled NER) pathway, 
which is activated by lesions in DNA regions 
involved in transcription (transcriptomes). In both 
cases, the unfolding of the double DNA helix is 
assured by the helicases XPD (polarity 3'-5') and 
XPB (polarity 5'-3') [Scharer, 2003]. This process 
renders the lesion accessible to the endonuclease 
XPG, which, in conjunction with the helicase XPA, 
recognizes and veriﬁ  es the presence of the DNA 
lesion and subsequently performs the incision of 
the damaged nucleotide in the 3' edge of the lesion 
(Fig. 2). In a third critical step, the endonuclease 
XPF, in association with ERCC1, removes the 
damaged nucleotide from the 5' edge of the dam-
aged chain and deliberates a fragment of 24–32 
bases [Fiedberg, 2001; Hoeijmakers, 2001]. 
Finally, a complex of DNA polymerases and 
ligases are recruited in order to perform the syn-
thesis of missing complementary nucleotides and 
3'
5' 3'
5'
ERCCI-
XPF
TFIIH
XPA XPC-
HR23B
RPA
XPG
Figure 2. The main molecules that participate in the necleotide excision repair (NER) process. ERCC1: Excision repair cross-complementation 
group 1, XPA: Xeroderma pigmentosum A DNA helicase, XPF and XPG: Xeroderma pigmentosum F and G DNA endonucleases. TFIIH, 
RPA and XPC-HR23B: Molecular complexes for the recognition of the lesion and the incision of the damaged nucleotide. Reproduced with 
permission.222
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restore normal nucleotide sequence in the damaged 
chain [Fiedberg, 2001; Hoeijmakers, 2001].
ERCC1 and DNA damage repair
In human cells, ERCC1 is a 15-kb gene located on 
the chromosome arm 19q and encodes for a nuclease 
of about 33 kDa. ERCC1 has been highly preserved 
during evolution and is constitutively expressed in 
all tissues at relatively high levels. The knock down 
of the ERCC1 gene in mice leads to an accelerated 
ageing phenotype with brain damage, liver failure 
and death shortly after weaning [Nunez et al. 2000]. 
Importantly, the ERCC1 protein is one of the rate-
limiting enzymes in the NER complex [Volker et al. 
2001], together with its obligate partner, the xero-
derma pigmentosum group F (XPF) protein. A cor-
relation between the expression of ERCC1 and 
resistance to platinum compounds has been consis-
tently suggested in patients with advanced-stage 
gastric, ovarian, colorectal, esophageal and non 
small-cell lung cancer [Altaha et al. 2004; Dabholkar 
et al. 1992; Dabholkar et al. 1994; Langer et al. 2005; 
Joshi et al. 2005; Reed et al. 2000; Metzger et al. 
1998; Lord et al. 2002; Rosell et al. 2002; Shirota 
et al. 2001; Warnecke-Eberz et al. 2004].
ERCC1 as a risk stratiﬁ  er 
in non small-cell lung cancer
A decade ago, a world-wide individual data-based 
meta-analysis [NSCLC collaborative group, 1995] 
suggested that cisplatin-based chemotherapy 
improved overall survival in advanced non small-
cell lung cancer (NSCLC). Since then, several 
trials in the adjuvant setting have been conducted 
and recent results showed that platinum-based treat-
ment improves survival by 4%–15%, depending on 
the TNM stage of the disease at diagnosis, among 
patients with surgically resected NSCLC [Scagliotti 
et al. 2003; Douillard et al. 2006; Winton et al. 2005; 
IALT collaborative group, 2004; Le Chevalier et al. 
2005; Strauss et al. 2004]. Among these trials, the 
International Adjuvant Lung Cancer Trial (IALT) 
that included more than 1,800 patients demon-
strated a 14%-decrease in individual risk of death 
and a 4.1% absolute beneﬁ  t in 5-year overall sur-
vival for patients treated with adjuvant cisplatin-
based chemotherapy [IALT collaborative group, 
2004]. Although platinum-based chemotherapy 
presently remains the “standard” in advanced 
NSCLC, not all patients derive substantial clinical 
beneﬁ  t from such a treatment. As a consequence, 
the IALT-bio study group prospectively collected 
tumor specimens from the IALT patients in an effort 
to identify molecular biomarkers that could 
determine responsiveness to platinum-based 
chemotherapy. In this recent work, ﬁ  ndings con-
cerning ERCC1 immunohistochemical expression 
on 761 tumors from the IALT study were reported 
[Olaussen et al. 2006]. ERCC1 immunohisto-
chemical expression in the tumour samples was 
dichotomized to either “high” or “low”, using the 
median value of ERCC1 expression as the “cut off” 
value. Consistent with the above-mentioned studies 
in other solid tumours, high ERCC1 expression was 
correlated with better prognosis in patients that had 
not received chemotherapy. On the other hand, an 
inverse correlation was identiﬁ  ed when patients 
were treated with cisplatin-based chemotherapy, 
meaning that the beneﬁ  t from adjuvant chemo-
therapy was more profound in patients with low 
ERCC1 expression. It was concluded that NSCLC 
patients with completely resected ERCC1 negative 
tumors seem to derive a substantial beneﬁ  t from 
adjuvant cisplatin-based chemotherapy compared 
to those with resected ERCC1 positive tumors.
The above-mentioned conclusion is consistent 
with recent ﬁ  ndings from other studies: Zhou et al. 
[Zhou et al. 2004] demonstrated that an increased 
number of variant alleles in ERCC1 that render the 
molecule less efficient was associated with a 
decreased overall survival in patients with advanced 
NSCLC treated with platinum agents and that the 
number of these alleles could be predictive for over-
all survival. Isla et al. [Isla et al. 2004] studied a 
single nucleotide polymorphism in ERCC1 in 
peripheral blood lymphocytes from patients with 
advanced disease treated with cisplatin-based che-
motherapy and concluded that patients with tumours 
bearing the polymorphism had a signiﬁ  cantly better 
survival. Moreover, Rosell and colleagues performed 
different studies examining the role of both ERCC1 
and RRM1 mRNA expression in parafﬁ  n-embedded 
pretreatment bronchial biopsies from patients 
with advanced NSCLC [Rosell et al. 2006; Rosell 
et al. 2003; Rosell et al. 2004]. Low ERCC1 mRNA 
levels were associated with better median sur-
vival in patients who received cisplatin-based 
chemotherapy. Bepler et al. [Bepler et al. 2006] 
recently reported an analysis of RRM1 and ERCC1 
gene expression in relation with tumor response. 
Their results suggest that ERCC1 and RRM1 
expression evaluated by real-time RT-PCR are predictors 223
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of tumor response in patients treated with the 
gemcitabine-platinum doublet regimen. In another 
retrospective analysis of 70 selected formalin-
fixed, paraffin-embedded lung tumour biopsies, 
Ceppi et al. [Ceppi et al. 2006] studied patients 
treated either with the combination of cisplatin and 
gemcitabine, or with gemcitabine alone. They also 
reported that patients presenting low ERCC1 tumor 
expression had a longer median survival than those 
with high ERCC1 expression. Finally, in a recent 
retrospective study [Azuma K et al. 2007], immuno-
histochemical expression of ERCC1 was able to 
predict progression-free and overall survival in 
patients receiving platinum-based chemotherapy for 
recurrent tumours after curative resection. Similar 
conclusions have been recently reported for limited-
stage small-cell lung cancer (SCLC) treated with 
platinum-based chemotherapy [Lee et al. 2007]. A 
summary of the clinical trials associating ERCC1 function 
with response to platinum-based chemotherapy in 
NSCLC patients is presented in Table 1.
Clinical prospective trials on ERCC1
After the encouraging results of a prospective phase 
II study customizing chemotherapy according to 
ERCC1 gene expression [Simon G et al. 2007], 
Cobo et al. recently published the results from a 
prospective phase III randomized trial [Cobo et al. 
2007], customizing cisplatin administration based 
on quantitative ERCC1 mRNA expression in 
tumours from patients with metastatic disease. The 
authors hypothesized that patients receiving therapy 
according to their baseline tumor ERCC1 mRNA 
levels would achieve higher response rates and 
more prolonged survival than patients in the control 
arm receiving non-customized therapy. Patients in 
the control arm received docetaxel plus cisplatin, 
Table 1. Main clinical trials associating ERCC1 function with response to platinum-based chemotherapy in NSCLC 
patients.
Author N Evaluation Method of analysis Conclusion
Olaussen et al. [29] 761 Retrospective ERCC1 IHC 
expression
ERCC1 negative tumours 
derive beneﬁ  t from cisplatin-
based chemotherapy
Zhou et al. [50] 128 Retrospective RT-PCR for ERCC1 
polymorphisms 
(C8092A)
Increased number of 
variant ERCC1 alleles 
associated with decreased 
overall survival
Isla et al. [18] 62 Retrospective RT-PCR for ERCC1 
SNPs in mRNA from 
peripheral blood 
lymphocytes
Patients bearing the 
homozygous 118C allele 
have a signiﬁ  cantly better 
survival
Rosell et al. [32–34] 100 Retrospective RT-PCR for ERCC1 
mRNA
Low ERCC1 mRNA levels 
associated with better 
median survival
Ceppi et al. [8] 70 Retrospective RT-PCR for ERCC1 
mRNA
Low ERCC1 mRNA levels 
associated with better 
median survival
Azuma et al. [2] 67 Retrospective ERCC1 IHC 
expression
ERCC1 ICH expression is 
prognostic for survival after 
cisplatin-based chemo-
therapy
Bepler et al. [5] 54 Prospective 
phase II
RT-PCR for ERCC1 
gene
ERCC1 expression predic-
tive of tumor response
Simon G et al. [40] 60 Prospective 
phase II
RT-PCR for ERCC1 
gene
ERCC1 expression predic-
tive of tumor response
Cobo et al. [9] 444 Prospective 
phase III
RT-PCR for ERCC1 
mRNA
ERCC1 mRNA levels can 
be used to customize 
therapy in the clinical 
setting224
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while patients in the experimental arm received 
either the same combination, if their ERCC1 mRNA 
levels were low, or docetaxel plus gemcitabine, if 
their ERCC1 levels were high. Among the 444 
patients enrolled in the study, 346 patients were 
evaluable for response. Objective response rates 
were 39.3% in the control arm and 50.7% in the 
experimental arm (p = 0,027). This study showed 
for the ﬁ  rst time that assessment of ERCC1 mRNA 
expression in tumour tissue is feasible in the clini-
cal setting in order to predict response to platinum-
based chemotherapy (Table 1).
Applicability of ERCC1 
Measurements in Clinical Practice
Current data suggest that ERCC1 is a potentially 
useful marker for predicting clinical resistance to 
platinum compounds such as cisplatin, carboplatin 
and oxaliplatin. However, no study has yet 
provided robust evidence to consider ERCC1 as 
a marker for resistance to all types of chemo-
therapy. Before the potential of ERCC1 as a pre-
dictor of chemosensitivity can be fully evaluated, 
several technical and practical obstacles should 
be addressed.
First, the diagnosis is made from small tumor 
samples (biopsies) with limited quantity of bron-
chial tissue. Since ERCC1 immunostaining is 
characterized by heterogeneity [Olaussen et al. 
2006], suboptimal sampling might mean that the 
biopsy is not necessarily representative of the 
whole tumour. Furthermore, tumour material could 
be obtained either from the primary or the meta-
static sites. This may be signiﬁ  cant since it has not 
been shown that ERCC1 expression is identical in 
the primary tumour and its metastatic locations.
Secondly, studies associating ERCC1 with resis-
tance to platinum compounds have been so far 
conducted mainly by DNA or RNA molecular 
analysis, which is both technically demanding and 
expensive. The IALT-bio study had the advantage 
of using immunohistochemistry to assess ERCC1 
expression, which is a feasible technique in every-
day practice of a pathology laboratory. Should the 
technical aspects of ERCC1 immunohistochemistry 
become standardized and optimized, this methodol-
ogy could rapidly be translated into a clinical real-
ity after other conﬁ  rmatory prospective studies. 
Currently, however, difﬁ  culties including the iden-
tiﬁ  cation of an optimal “cut-off” value for ERCC1, 
the subjectivity of the pathological examination, 
particularly in prospective studies, and the hetero-
geneity of staining, that renders the technique of 
tissue micro-arrays rather inapplicable, limit the 
clinical usefulness of such procedures. Other dif-
ﬁ  culties, such as different genetic backgrounds in 
the population, or interaction with smoking habits, 
should be further discussed. In any case, meticulous 
methodological considerations and standardization 
are mandatory. It is necessary that future larger and 
prospective studies should be extensively discussed 
within multidisciplinary groups including highly 
skilled pathologists and bio-statisticians.
Future perspectives and challenges
In the future, it seems probable that patients with 
ERCC1 positive tumours will be treated with non-
platinum based regimens, whereas patients with 
ERCC1 negative tumours will be considered as 
optimal candidates for platinum-based therapy. In 
chemo-naïve patients, high ERCC1 expression is 
associated with a better prognosis since it provides 
the cell with a more competent DNA repair mech-
anism. Indeed, such a dual role of the ERCC1 
protein is in agreement with recent proposals con-
sidering that DNA repair acts as a “double-edged 
sword” [Wei et al. 2000]. According to this theory, 
low DNA repair capacity allows for higher genomic 
instability within the cancer cell and consequently 
a faster acquisition of more aggressive malignant 
characteristics in chemo-naïve patients. On the 
other hand, at the same time it also predicts good 
response to DNA-targeting compounds because it 
deprives cancer cells from adequate DNA repair 
mechanisms. Globally, it also suggests the possibil-
ity that ERCC1 might have alternative functions 
in cancer cells. It is not yet known why ERCC1 is 
essential for life, whereas other limiting proteins 
in the NER repair pathway are not (such as XP 
patients carrying mutations in XPA, -B, -C, -D, -F, 
or G). There is clearly a need for a better under-
standing of the alternative functions of ERCC1, 
and further research in fundamental biology is 
highly awaited.
Conclusion
Platinum-based chemotherapy improves survival of 
patients with non small-cell lung cancer, but not 
all patients derive therapeutic beneﬁ  t from this treat-
ment. Emerging evidence suggests the association 
of the molecular characteristics of the tumour with 225
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responsiveness to platinum-based chemotherapy. 
The DNA repair protein ERCC1, which is both a 
prognostic marker for survival and a predictor for 
response to platinum compounds, is currently an 
attractive molecular marker undergoing clinical 
testing in order to allow a more selective therapeu-
tic strategy. Nevertheless, important issues regarding 
standardization and optimization of technical pro-
cedures for ERCC1 analysis in tumor samples 
remain to be resolved before this methodology can 
be implemented in daily clinical practice.
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